Abstract:Importance: Underrepresentation of many racial/ethnic groups in Alzheimer disease (AD) clinical trials limits generalizability of results and hinders opportunities to examine potential effect modification of candidate treatments.Objective: To examine racial and ethnic differences in recruitment methods and trial eligibility in a multisite preclinical AD trial.Design, Setting, and Participants: This cross-sectional study analyzed screening data from the Anti-Amyloid in Asymptomatic AD study, collected from April 2014 to December 2017. Participants were categorized into 5 mutually exclusive ethnic/racial groups (ie, Hispanic, Black, White, Asian, and other) using participant self-report. Data were analyzed from May through December 2020 and included 5945 cognitively unimpaired older adults between the ages of 65 and 85 years screened at North American study sites.Main Outcomes and Measures: Primary outcomes included recruitment sources, study eligibility, and ineligibility reasons. To assess the probability of trial eligibility, regression analyses were performed for the likelihood of being eligible after the first screening visit involving clinical and cognitive assessments.Results: Screening data were included for 5945 participants at North American sites (mean [SD] age, 71.7 [4.9] years; 3524 women [59.3%]; 5107 White [85.9%], 323 Black [5.4%], 261 Hispanic [4.4%], 112 Asian [1.9%], and 142 [2.4%] who reported race or ethnicity as other). Recruitment sources differed by race and ethnicity. While White participants were recruited through a variety of sources, site local recruitment efforts resulted in the majority of Black (218 [69.2%]), Hispanic (154 [59.7%]), and Asian (61 [55.5%]) participants. Participants from underrepresented groups had lower mean years of education (eg, mean [SD] years: Hispanic participants, 15.5 [3.2] years vs White participants, 16.7 [2.8] years) and more frequently were women (226 [70.0%] Black participants vs 1364 [58.5%] White participants), were unmarried (184 [56.9%] Black participants vs 1364 [26.7%] White participants), and had nonspousal study partners (237 [73.4%] Black participants vs 2147 [42.0%] White participants). They were more frequently excluded for failure to meet cognitive inclusion criteria (eg, screen failures by specific inclusion criteria: 147 [45.5%] Black participants vs 1338 [26.2%] White participants). Compared with White participants, Black (odds ratio [OR], 0.43; 95% CI, 0.34-0.54; P < .001), Hispanic (OR, 0.53; 95% CI, 0.41-0.69; P < .001), and Asian participants (OR, 0.56; 95% CI, 0.38-0.82; P = .003) were less likely to be eligible after screening visit 1.Conclusions and Relevance: Racial/ethnic groups differed in sources of recruitment, reasons for screen failure, and overall probability of eligibility in a preclinical AD trial. These results highlight the need for improved recruitment strategies and careful consideration of eligibility criteria when planning preclinical AD clinical trials.

The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

Sex Differences in Cognitive Resilience in Preclinical Autosomal-Dominant Alzheimer's Disease Carriers and Non-Carriers: Baseline Findings from the API ADAD Colombia Trial

Sex and gender differences in Alzheimer’s disease: current challenges and implications for clinical practice

Unveiling sex-based differences in Parkinson's disease: a comprehensive meta-analysis of transcriptomic studies

Sex differences in dementia diagnosis: a fourteen-year retrospective analysis of cases using the Registry of Dementia of Girona

Sex Differences in Blood Biomarkers and Cognitive Performance in Individuals with Autosomal Dominant Alzheimer's Disease.

Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective

Association of biological sex with clinical outcomes and biomarkers of Alzheimer's disease in adults with Down syndrome

A case for seeking sex-specific treatments in Alzheimer's disease

Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology

Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study

Reproductive Health Data and Its Relationship to Baseline Brain Imaging and Cognitive Measurements in Cognitively Unimpaired Female PSEN1 E280A Mutation Carriers and Non‐carriers from the API ADAD Trial

The role of microRNAs in understanding sex-based differences in Alzheimer's disease

Sex differences in Alzheimer disease - the gateway to precision medicine

Sex and gender considerations in Alzheimer's disease: The Women's Brain Project contribution

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial

Gender differences in the moderating capacity of reserve and resilience factors on the association of Alzheimer’s disease brain pathology and cognitive function

Serum metabolome profiling in patients with mild cognitive impairment reveals sex differences in lipid metabolism

Symposium 08: Neuropsychological Considerations for Alzheimer's Disease Clinical Trials

Design of a Non-Interventional Study to Assess Neurologists' Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease

Sex Differences in Alzheimer's Disease: Where Do We Stand?